TG6002
TG6002, multifunctional oncolytic virus
A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the tumor.
TG6002 aims to attack solid tumors on multiple “fronts” while avoiding the side effects of chemotherapy.
Discover how TG6002 works
Sale of the rights in China
Tasly Biopharmaceutical Group Co, Ltd. acquired research, development and commercialization rights of the technology of TG6002 (T601) for Greater China in 2018. >>read the press release
First promising results
Transgene is developing TG6002 for the treatment of several solid tumors, such as gastro-intestinal adenocarcinoma (stomach, pancreas and colon). Phase I interim results demonstrate that after IV infusion, TG6002 was detected in the tumor and induced the production of 5-FU. No major SAE have been observed.
Poster presented at ESMO 2021
Attacking the tumor on several fronts
TG6002 combines several mechanisms of action to:
- directly and selectively destroy the cancer cells (oncolysis) by causing immunogenic cell death;
- induce an immune response,, following the release of antigens during the oncolysis;
- allow the production of chemotherapy (5-FU), directly in the tumor..
Ongoing clinical trials
| Indication | Phase | |
|---|---|---|
| Colorectal cancer – IV route | Phase I/IIa | More information |
| Colorectal cancer – IHA route | Phase I/II | More information |
- September 16, 2021 - Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
- April 9, 2021 - Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses
- September 8, 2020 - Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
>> All press releases
- Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer
A. Samson et al.
AACR 2023
Download the poster here
Poster Presentation - Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
V. Moreno et al.
ESMO 2022
Download the poster here
Poster Presentation - 3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Hélène Lê et al.
EUROoCS 2021
Download the Poster here
Poster Presentation